



PATENT

Attorney Docket No. 30311/35918

IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE

Applicants:) I hereby certify that this paper is being
Drmanac *et al.*) deposited with the United States Postal
Serial No.: 09/479,608) Service as first class mail, postage prepaid,
Filed: January 6, 2000) in an envelope addressed to:
For: ENHANCED) Commissioner for Patents, Washington,
SEQUENCING BY) DC 20231, on this date:
HYBRIDIZATION) August 20, 2002
USING POOLS OF)
PROBES)
Group Art Unit: 1631)
Examiner: L. Clow)
Nabeeela McMillian
Reg. No. 43,363
Agent for Applicants

H23
Plunkett
1/22/03

**STATEMENT CONCERNING COMMON OWNERSHIP OF ALFENITO (U.S.
PATENT NO. 6,355,419) AND U.S. PATENT APPLICATION NO. 09/479,608**

Commissioner for Patents
Washington, DC 20231

Sir:

The undersigned representative states that:

1. U.S. Patent No. 6,355,419, hereinafter "Alfenito" issued from U.S. Patent Application Serial No. 09/067,317.

2. U.S. patent application number 09/479,608 (hereinafter "the '608 application"), was filed on January 6, 2000. At that time, the inventors of both Alfenito and the '608 application were under an obligation to assign their inventions to the same entity, namely Hyseq Inc. Such assignments were duly executed and recorded as explained herein below.

3. The inventor of U.S. Application Serial No. 09/067,317, Mark R. Alfenito, assigned the Alfenito invention to Hyseq, Inc. This assignment was duly

recorded with the United States Patent and Trademark Office at reel and frame number 9377/0102. (Attached as Exh. 1)

4. Subsequently, Hyseq Inc., assigned the rights to Alfenito invention to Callida Genomics, Inc. This assignment was duly recorded with the United States Patent and Trademark Office at reel and frame number 012716/0954. (Attached as Exh. 2).

5. U.S. patent application number 09/479,608 (hereinafter the '608 Application), was assigned by the inventors to Hyseq, Inc., March 22, 2002. This assignment was duly recorded with the United States Patent and Trademark Office at reel and frame number 010716/0409. (Attached as Exh. 3).

6. Subsequently, Hyseq Inc., assigned the rights to the '608 Application to Callida Genomics, Inc. This assignment was filed with the United States Patent and Trademark Office on March 5, 2002. (Attached as Exh. 4).

7. The above evidence demonstrates that at the time the '608 application was filed, the inventors listed on both the Alfenito patent and the '608 application were under an obligation to assign their inventions to the same entity.

Respectfully submitted,
MARSHALL, GERSTEIN & BORUN

By:


Nabeela McMillan
Registration No. 43,363
Attorneys for Applicants
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

Chicago, Illinois
August 20, 2002